SANTA ANA, Calif.— Federal prosecutors say the former CEO of a Southern California medical device company has been indicted on allegations that he shared insider trading secrets with former Baltimore Orioles All-Star Doug DeCinces.
*Action may deter Pfizer from returning to bid for AstraZeneca. WASHINGTON/ NEW YORK, Sept 23- Tough new U.S. rules on corporate "inversions" on Tuesday sent a chill through the market for the tax-avoidance deals, both pending and potential, with share prices falling sharply in nearly a dozen companies on both sides of the Atlantic.
*Action may deter Pfizer from returning to bid for AstraZeneca. Burger King, which is in the process of an inversion deal with Canada's Tim Horton's, said Tuesday it would proceed with its $11.5 billion deal despite the Treasury actions, saying the transaction was not about the tax benefits.
*May deter Pfizer from returning to bid for AstraZeneca. LONDON, Sept 23- Shares in drugmakers AstraZeneca and Shire fell sharply on Tuesday after the U.S. The move could jeopardize an agreed deal for AbbVie to buy Shire for $55 billion and deter Pfizer from making another attempt to acquire AstraZeneca, after a $118 billion takeover attempt failed in May.
The FTC, which says AndroGel users paid hundreds of millions of dollars more than necessary because of the companies' actions, asked the U.S. District Court for the Eastern District of Pennsylvania to order AbbVie to refund users that money.
SHANGHAI, Aug 25- The entanglement of H.J. Heinz Co. in China's latest food scare highlights a key concern for international and local firms- how to keep track of ingredients from diverse sources in a country where food supply tracing technologies are far from the norm.
WASHINGTON, Aug 7- An influential U.S. senator is encouraging the Internal Revenue Service to stamp out deals that allow companies to relocate their headquarters overseas in search of lower tax rates.
*Expects key drug launches in fourth quarter despite FDA delay. Aug 7- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories, Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.
*Cuts top end of FY earnings forecast to $3.45/ shr from $3.60/ shr. Aug 7- Mylan Inc shaved the top end of its full-year revenue and earnings forecasts, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.
Can the Obamacare appeal jump right to the Supreme Court at this juncture? Law professor Dan Eaton explains.
SHANGHAI/ HONG KONG, July 29- With green-tea flavoured toothpaste and pickled plum juice, an army of Chinese retailers is tapping local tastes to whittle away market share from global rivals that are banking their future growth on the world's second-largest consumer market.
Some of the names on the move ahead of the open.
Surely Congress didn't mean to include a "poison pill" for the Affordable Care Act when it passed it, says law professor Tim Jost.
After a split ruling on Obamacare from the courts, who gets the last word? Law professor Dan Eaton weighs in.
LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.
Do US firms have a duty to sacrifice their own interests for the broader good of the country?, asks law professor Dan Eaton.
Some of Wednesday's midday movers:
*Sanofi mulls fate of 200 older drugs including Plavix. *Sanofi also held talks with TPG and Warburg Pincus. PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.
Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.
PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.